Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer

[1] Govindan R(2011)Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer J Thorac Oncol 6 790-795

[2] Morgenzstern D(2004)Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589-1597

[3] Kommor MD(2009)S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer Gan To Kagaku Ryoho 36 963-967

[4] Herbst RS(1999)Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000-2005

[5] Schaefer P(2001)Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 939-943

[6] Gandhi J(1997)Determination of S-1 (combined drug of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry J Chromatogr B Biomed Sci Appl 691 95-104

[7] Saito K(2007)Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan Ann Oncol 18 317-323

[8] Zergebel C(2009)Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with met amplification Clin Cancer Res 15 907-913

[9] Schiller J(2008)Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol Cancer Ther 7 599-606

[10] Hanna N(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98

[1] Govindan R(2011)Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer J Thorac Oncol 6 790-795

[2] Morgenzstern D(2004)Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589-1597

[3] Kommor MD(2009)S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer Gan To Kagaku Ryoho 36 963-967

[4] Herbst RS(1999)Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000-2005

[5] Schaefer P(2001)Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 939-943

[6] Gandhi J(1997)Determination of S-1 (combined drug of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry J Chromatogr B Biomed Sci Appl 691 95-104

[7] Saito K(2007)Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan Ann Oncol 18 317-323

[8] Zergebel C(2009)Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with met amplification Clin Cancer Res 15 907-913

[9] Schiller J(2008)Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol Cancer Ther 7 599-606

[10] Hanna N(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98